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Purpose. This review provides an overview of the proceedings of the 
symposium “Tackling the Challenges of Nanomedicines: Are We Ready?” 
organized by the International Pharmaceutical Federation (FIP) Hospital 
Pharmacy Section and Non-Biological Complex Drugs (NBCDs) Work-
ing Group at the 2019 FIP World Congress of Pharmacy and Pharma-
ceutical Sciences. Debate centered on reasons underlying the current 
complex regulatory landscape for nanomedicines and their follow-on 
products (referred to as nanosimilars) and the pivotal role of hospital phar-
macists in selecting, handling, and guiding usage of nanomedicines and 
nanosimilars.
Summary. The evaluation and use of nanomedicines are recognized 
among scientific, pharmaceutical, and regulatory bodies as complex. 
Interchangeability and substitutability of nanomedicines and nanosimilars 
are confounded by a lack of pharmaceutical and pharmacological equiva-
lence, reflecting the inherent complex nature of these drug products and 
manufacturing processes. Consequences include implications for clinical 
safety and efficacy and, ultimately, comparability. Local regulatory approv-
als of some nanomedicines have occurred, but there is no standard to en-
sure streamlined evaluation and use of consistent measures of therapeutic 
equivalence of reference products and their nanosimilars. Hospital phar-
macists are expected to be experts in the selection, handling, and substi-
tution of nanomedicines and familiarize themselves with the limitations of 
current methods of assessing pharmaceutical and clinical equivalence of 
nanosimilars in order to ensure informed formulary decision-making and 
eventual patient benefit.
Conclusion. Supportive guidance for pharmacists focusing on the substi-
tutability and/or interchangeability of nanomedicines and their nanosimilars 
is needed. Current FIP guidance for pharmacists on therapeutic inter-
change and substitution should be extended to include nanomedicines 
and nanosimilars.
Keywords: nanomedicine, nanosimilars, pharmacists, substitution, thera-
peutic equivalency
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A large and steadily growing body of literature focuses on nanomedicine 
and the challenges of the interchange-
ability or substitution of nanomedicines 
and their follow-on products, also 
referred to as nanosimilars.1-3 In 
September 2019, the International 
Pharmaceutical Federation (FIP) 
Hospital Pharmacy Section4 and the 
FIP Non-Biological Complex Drugs 
(NBCDs) Working Group5 organized a 
precongress satellite symposium at the 
79th FIP World Congress of Pharmacy 
and Pharmaceutical Sciences in 
Abu Dhabi, United Arab Emirates.6 
Chaired by authors Shah and Hertig, 
the symposium included presenta-
tions by 4 speakers (authors Flühmann, 
Mühlebach, Shah, and Stemer) that 
provided scientific, industrial, clin-
ical practice, and hospital pharmacy 
perspectives on current challenges in 
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nanomedicine and appropriate use 
and evaluation of nanosimilars. Here 
we provide an overview of the topics 
covered and discussed during the ses-
sion, which emphasized the import-
ance of promoting wider understanding 
of nanomedicines and the innovation 
behind them. Those topics included 
consideration of the challenges arising 
from the potential impact of dispar-
ities between reference nanomedicine 
products and nanomedicines to en-
sure their safe and effective use in clin-
ical practice. Presentations explored 
differences between nanomedicines 
and conventional small-molecule 
drugs and reasons for the current 
complex regulatory landscape for 
nanomedicines and nanosimilars. 
Finally, the symposium analyzed the 
pivotal role of hospital pharmacists 
in decisions on product selection and 
usage due to their expected biomed-
ical understanding of drugs’ efficacy 
and safety profiles and their impact on 
patient treatment. Debate led to the 
conclusion that there was a need for re-
vision of the 2018 FIP policy document 
“Pharmacist’s Authority in Product 
Selection: Therapeutic Interchange 
and Substitution” to include guidance 
on nanomedicines and their follow-on 
products.7
What are nanomedicines?
There is no universally accepted 
definition of nanomedicine. The term 
nanomedicine describes the use of 
nanotechnology in biomedical sci-
ence and healthcare and encom-
passes a wide range of therapeutic 
and diagnostic applications.1,2,8 The 
European Medicines Agency (EMA) 
designates nanomedicine as “the ap-
plication of nanotechnology in view of 
making a medical diagnosis or treating 
or preventing diseases” through ex-
ploiting the properties of materials 
at nanometer scale (approximately 
0.2-100  nm).9 In the United States, 
the Food and Drug Administration 
(FDA) follows a more restrictive ap-
proach, considering both size (ma-
terials with nanoscale dimensions of 
approximately 1-100 nm) and function 
(whether physical or chemical prop-
erties or biological effects are attribut-
able to dimensions up to 1,000 nm) to 
determine whether a product involves 
nanotechnology.10 In 2017, FDA issued 
a draft guidance on drug products that 
contain nanomaterials.11,12
Nanomedicines are already a reality 
of modern healthcare. A  PubMed 
search for “nanomedicine” in April 
2020 retrieved 30,637 results. In a re-
view of nanomaterial submissions to 
FDA from 1973 through 2015, 20 dif-
ferent categories of nanomaterials were 
listed,13 with nanoparticle structures 
ranging from solid or functionalized 
nanoparticles to nanoshells, nano-
tubes, and nanoliposomal vesicles.14 
Nanomedicines have already been ap-
plied to a broad spectrum of medical 
specialties, often for chronic and severe 
diseases—for example, iron deficiency 
anemia,15,16 fungal infections and leish-
maniasis,17,18 chronic dry eye disease,19 
cancers,20,21 and multiple sclerosis.22,23 
Liposomes, nanocrystals (introduced 
mainly for increasing the solubility/
bioavailability of oral drugs24) and iron-
carbohydrate complexes comprise 
more than two-thirds of nanomedicine 
product submissions to FDA.13 There is 
also increasing discussion surrounding 
nanomedicines and their integration 
into healthcare, a theme explored in 
a June 2018 webinar series presented 
by the hospital pharmacy section of 
FIP.25-27
Why “go nano” in 
therapeutics?
Almost all materials can be nano-
sized. The reduction in particle size 
gives rise to specific properties that dif-
ferentiate nanomedicines from other 
drug products.10,14 One determinant of 
the fate of nanomedicines upon ad-
ministration is the interaction of their 
surface with the biological environ-
ment (Figure 1). Nanoparticle size, 
size distribution, morphology, and 
surface characteristics all influence 
drug delivery, pharmacokinetics, and 
pharmacodynamics as well as the tox-
icity and immunogenicity profiles of a 
drug product.28,29 Interactions with bio-
logical systems, such as translocation 
routes into cells or reactivity with cells 
and cellular components, are also im-
pacted.30 For example, nanonization 
and surface modification can impact 
the biodistribution of colloidal drugs, 
altering cellular and organ-level up-
take to allow selective or preferen-
tial drug targeting,29,31 thus impacting 
pharmacokinetics.
The particular properties of 
nanomedicines associated with their 
nanoscale dimensions can lead to 
certain therapeutic advantages. For 
example, paclitaxel protein-bound par-
ticles (Abraxane, Celgene Corporation, 
Summit, NJ) are a type of nanomedicine, 
comprising specifically engineered 
paclitaxel-loaded albumin moieties, li-
censed for use for several oncology indi-
cations, including metastatic non–small 
KEY POINTS
 • Interchangeability of refer-
ence nanomedicines and their 
follow-on products is not sup-
ported by well-defined equiva-
lence evaluations; growing 
evidence shows adverse clin-
ical and cost implications with 
use of nanosimilars.
 • For patient safety and benefit, 
regulatory approval processes 
for nanosimilars need to be 
better defined and stand-
ardized across agencies to 
support consistent evaluation 
of critical quality attributes 
as evidence of therapeutic 
equivalence to reference 
nanomedicines.
 • Pharmacists would benefit from 
additional education and guid-
ance on interchangeability of 
nanosimilars; in support, current 
International Pharmaceutical 
Federation guidance on thera-
peutic interchange and substi-
tution should be updated.
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cell lung carcinoma.20,21 They were de-
veloped as a solvent-free taxane-based 
medicine to overcome hypersensi-
tivity reactions and toxicity associated 
with a previous formulation in which 
amphiphilic solvents were used to solu-
bilize lipophilic paclitaxel.32 Preclinical 
evidence suggests that the specific 
albumin-mediated and stabilized col-
loidal formulation of paclitaxel protein-
bound particles could also facilitate 
penetration of the blood-brain barrier 
to enable targeting of brain tumors.33,34 
Polyethylene glycol (PEG) conjugation 
is another strategy that may offer bene-
fits in nanomedicine delivery. In an 
example of use of this technology, PEG-
conjugated liposomal doxorubicin 
(pegylated liposomal doxorubicin 
hydrochloride [Doxil/Caelyx; Janssen 
Biotech, Inc., Horsham, PA]) improves 
plasma stability and half-life compared 
with either nonpegylated liposomal 
doxorubicin (Myocet liposomal; Teva 
Pharmaceutical Industries Ltd, Petah 
Tikva, Israel) or free doxorubicin 
(Adriamycin; Pfizer Inc., New York, 
NY). The higher in vivo stability of PEG-
conjugated nanomedicine results in an 
increased tumor exposure with a lower 
total dose and, as a consequence, re-
duced toxicity (associated with free 
and total-dose doxorubicin) relative 
to the other doxorubicin formulations, 
increasing its efficacy and thereby 
improving the therapeutic index.28,35,36
Challenges in demonstrating 
therapeutic equivalence of 
nanomedicines and follow-on 
products
Nanomedicines are complex in 
composition and structure and will 
therefore also fall into the pharma-
ceutical class of non-biological com-
plex drugs (NBCDs)—a term coined in 
2012 based on a concept first arising 
at a workshop in 2009.37,38 NBCDs are 
considered to be complex drugs that 
are not biologics but, in common 
with biologics, lack a homogeneous 
molecular structure that cannot be 
fully isolated or characterized on the 
basis of chemical structure alone.39 
Instead, a specific set of orthogonal 
physicochemical analytical methods 
must be applied and complemented 
in a weight-of-evidence approach 
with nonclinical and human data to 
support similarity with a reference 
product.40 While neither FDA nor 
EMA currently accept NBCDs as con-
stituting a distinct category of drugs, 
FDA refers to “complex” drug prod-
ucts on the basis of factors including 
the complexity of the active ingre-
dient, formulations, delivery routes, 
and dosage forms.41,42 Examples of 
NBCDs include liposomes,17,18 emul-
sions,19 glatiramoids,22,23 and iron-
carbohydrate complexes,15,16 as well 
as albumin-bound nanoparticle 
anticancer drugs.20,21 In addition, 
nanomedicines are very sensitive to 
changes in manufacturing process 
conditions and production scales, 
which can affect a product’s quality 
and clinical profile, including batch-to-
batch consistency.12,43 With the quality 
and composition of nanomedicines 
highly dependent on sophisticated 
and difficult-to-control proprietary 
manufacturing processes, even small 
differences in process conditions may 
lead to differences in their critical 
quality attributes (CQAs).1 A  CQA is 
defined by the International Council 
for Harmonisation of Technical 
Requirements for Pharmaceuticals for 
Human Use as “a physical, chemical, 
Figure 1. Different surface structures of nanomedicines, which can affect their interaction with the biological environment. 
Adapted, with permission, from an original figure developed by Dr. Tom McDonald (University of Liverpool) for the British 
Society for Nanomedicine.
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biological, or microbiological prop-
erty or characteristic that should be 
within an appropriate limit, range, 
or distribution to ensure the desired 
product quality,” and CQAs must be 
defined for each nanomedicine. As 
of today, structure-function relation-
ship is not fully understood for many 
nanomedicines, and hence product-
specific CQAs might be ill defined for 
many approved drug products; this 
is a topic subject to ongoing scientific 
debate.24
Given the complexities of character-
izing nanomedicine structures as well 
as the limitations of standard assays, 
test protocols, and laboratory instru-
mentation,8 it is extremely challenging 
to fully demonstrate the pharmaceut-
ical equivalence of follow-on products 
to reference nanomedicines. A  report 
of the US Government Accountability 
Office indicated general agreement 
among representatives from FDA, 
manufacturers, and expert groups that 
demonstrating pharmaceutical equiva-
lence and bioequivalence of follow-on 
products to a reference nanomedicine 
is difficult.41 Given these challenges, 
it is inappropriate to apply the cur-
rently defined generics paradigm to 
nanomedicine regulation, which re-
quires determining both pharmaceut-
ical equivalence and bioequivalence 
in a comparability process for fully 
characterized small-molecule drug 
products.24,41 In addition, the com-
plex nature of nanomedicines and 
the known barriers in demonstrating 
therapeutic equivalence challenge the 
substitutability and interchangeability 
of reference and follow-on products.1,43 
Conventional bioequivalence testing 
(ie, measuring plasma drug concen-
trations) may not reflect the perform-
ance of nanomedicines, depending on 
administration route and different cel-
lular uptake mechanisms in target tis-
sues; as such, additional testing such 
as clinical studies may be required.41 
Furthermore, given the sensitivity of 
nanomedicines to manufacturing con-
ditions, specific, well-controlled, and 
robust manufacturing processes are 
fundamental to defining the product 
profile, quality, safety, efficacy, and 
consistency of nanosimilars.24,43
FDA and EMA differ in their no-
menclature and regulatory approach to 
nanosimilars, although both regulatory 
bodies recognize and are considering 
them in their guidance.41,44,45 FDA, for 
example, is supporting the develop-
ment of product-specific guidance for 
the development of “complex generic 
drug products.” 41 In terms of regula-
tory pathways, US and European Union 
(EU) policies are not harmonized and, 
as yet, there are no mutually accepted 
approval pathways for complex gen-
eric drug products and nanosimilars, 
respectively46; in fact, both the United 
States and EU evaluate these drug 
products on a case-by-case basis.11,42 
Furthermore, EU regulatory applica-
tion procedures have been noted to 
have been used inconsistently even 
within product classes.42
FDA draft guidance issued in 2017 
acknowledged the many challenges 
faced in manufacturing and approving 
nanomaterials, providing general re-
commendations on the approval of 
drugs containing nanomaterials and 
demonstration of pharmaceutical 
equivalence and bioequivalence for 
complex generic drug products.11,12 In 
addition, FDA has released product-
specific draft guidance for a number of 
nanomedicines.11 For the evaluation of 
complex generic drug products, FDA 
generally adopts a weight-of-evidence 
approach requiring stepwise and case-
by-case comparison to a reference 
drug.40 The 505(j) abbreviated new drug 
application pathway, recommended 
by FDA as the standard evaluation 
pathway for complex generic drug 
products, including those comprising 
nanomaterials, allows approval of a 
generic drug based on bioequivalence 
to the reference product.47 This pathway 
involves designation of the complex 
generic drug product as pharmaceut-
ically equivalent and bioequivalent, 
enabling marketing of the product 
as substitutable with the reference 
product.12 However, several experts 
have highlighted the problematic na-
ture of this approach.47 Application 
sponsors have the option of using the 
505(b)(2) pathway instead to establish 
the clinical safety and effectiveness of a 
given complex generic drug product.12 
Nevertheless, substitutability or inter-
changeability with a (closely) related 
reference drug remains unclear in 
the absence of clinical head-to-head 
analysis.
In Europe, nanomedicines have 
no dedicated regulatory pathway and, 
unlike biologics, can be approved via 
the decentralized EMA procedure, 
despite their complexity.42 In the 
past, nanosimilars marketed in EU 
member states have been approved 
using the generics pathway.42 Since 
2015, a totality-of-evidence approach 
to regulatory approval of nanosimilars 
has been increasingly adopted by 
EMA, which uses the so-called hybrid 
pathway authorized in Article 10(3) of 
Directive 2001/83/EC.42 In addition, 
EMA has released several reflection pa-
pers regarding selected nanomedicines 
and their nanosimilars, such as iron-
carbohydrate complexes and intra-
venous (IV) liposomal products, in 
order to address specific challenges 
and data requirements for particular 
products.48,49 These reflection papers 
detail the regulatory requirements for 
these products, including data require-
ments based on a stepwise totality-of-
evidence approach44,48,49 similar to the 
biosimilar approval pathway.50 In the 
case of nano-sized colloidal IV iron-
carbohydrate complexes, the approval 
of a similar product currently requires 
more than the conventional demon-
stration of bioequivalence to the refer-
ence nanomedicine, such as through 
establishing comparable plasma iron 
concentrations.48 Indeed, the stability 
of the iron-carbohydrate complex as 
well as its physicochemical properties 
has a strong influence on the in vivo 
fate and resulting toxicological and 
pharmacological effects, which must 
also be shown to be equivalent. This 
necessitates the provision of sufficient 
evidence of product quality, including 
the composition of the carbohydrate 
matrix, spectroscopic properties, 
amount of labile iron released from 
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the administered product, impurities, 
morphology, particle size, size distri-
bution, charge, and surface properties, 
as well as the degradation pathway 
for the iron-carbohydrate complex.48 
In addition, the pertinent EMA re-
flection paper48 recognizes the limi-
tations of quality characterization for 
nanomedicines, noting that this alone 
is insufficient to provide assurance of 
similarity between a reference product 
and proposed nanosimilar. Instead, 
data from quality, nonclinical, and 
human pharmacokinetic studies are re-
quired to support regulatory approval, 
with a potential for requirement of add-
itional clinical studies.48
Important issues remain to be ad-
dressed by both regulatory agencies, 
including the interchangeability and 
substitution of nanomedicines and 
nanosimilars. Therapeutic equivalence 
of 2 products enables them to be inter-
changed. Interchangeability can be ei-
ther at a population level, meaning that 
both products can be used to treat the 
same condition in the same popula-
tion, or at the individual level, meaning 
that 2 products can be switched during 
treatment of an individual patient.51 
Substitution is a policy that allows for 
replacement, at the individual level, 
of a medicinal product with a similar 
bioequivalent product.51 Some have ex-
pressed the view that recent FDA draft 
guidance on complex generic drug 
product approval pathways should be 
reconsidered, as the agency’s proposals 
do not adequately account for the com-
plexity of nanomedicines.47 Currently, 
EMA does not define substitution or 
interchange of follow-on products; 
this is decided at a national authority 
level by individual EU member states 
through application of heterogeneous 
and unclear rules.24,42,51 Indeed, chal-
lenges and deficiencies encountered 
in past approval processes have been 
highlighted by reports in the litera-
ture of lack of therapeutic equivalence 
and safety issues with some follow-on 
iron-carbohydrate complexes,52,53 as 
discussed in depth later in this art-
icle. Recently, a nanosimilar regu-
latory pathway more aligned with 
biosimilar approval pathways has been 
proposed,3,47 with proponents sug-
gesting the need for a comprehensive 
totality-of-evidence approach of step-
wise physicochemical characterization, 
nonclinical studies, and clinical com-
parative studies. Potentially, this could 
offer an alternative, more appropriate 
regulatory pathway for nanosimilar 
follow-on products.
Nanosimilar selection and 
substitution practice: the role 
of the pharmacist
The 2011 “Joint FIP/WHO Guidelines 
on Good Pharmacy Practice” recom-
mend that pharmacists are central to 
generic substitution.54 Hospital phar-
macists also have a key role in the se-
lection, handling, and substitution of 
nanomedicines, a class of drugs distinct 
from generics. Taking into account that 
there are US and EU regulatory path-
ways that do not establish therapeutic 
equivalence of follow-on products 
with their reference drugs, pharmacists 
need to be able to critically appraise the 
data for nanosimilars before making 
science-based recommendations for 
their inclusion in a hospital formulary; 
this includes familiarity with the con-
cept of pharmaceutical equivalence (ie, 
quality, including purity, physico- and 
immunochemical properties; biological 
activity; and formulation character-
istics) and bioequivalence (ie, com-
parability of pharmacokinetics as a 
prerequisite for clinical efficacy and 
safety).43,55,56 Alongside consideration of 
other criteria, decisions on formulary 
inclusion must be based on evidence of 
therapeutic equivalence in a relevant 
clinical setting.55
In 2017, an expert group identified 
specific formulary inclusion criteria for 
the evaluation of nanosimilar follow-on 
products and developed a structured 
tool to guide pharmacists’ evaluation 
of interchangeability and substitut-
ability (Figure 2).55 The following prop-
erties were considered key: particle size 
and particle size distribution, particle 
surface characteristics, the fraction of 
uncaptured bioactive moiety, the phys-
ical stability of the colloidal dispersion 
during storage and the stability of ready-
to-use preparations (ie, on dilution), 
and uptake and distribution.55 Without 
better understanding of the limitations 
of interchangeability and substitution 
of nanomedicines, the formulary evalu-
ation of nanosimilars may be limited 
to an analysis of procurement cost 
only, at the potential expense of safe 
and efficacious use of these drugs.56 
For biologicals, interchangeability is 
usually decided at the physician pre-
scribing level and is a prerequisite for 
substitution policies that allow for re-
placement of a prescribed medicine at 
the pharmacy dispensing level.51 Given 
that the same practice patterns may be 
adopted for the interchange and substi-
tution of nanomedicines, guidance and 
education are needed to guide pharma-
cists and other healthcare professionals 
involved in formulary decision-making 
regarding nanomedicines.43,55,56
In 2018, FIP published a statement 
of policy outlining the pharmacist’s 
role and authority in product se-
lection.7 The document focused on 
therapeutic interchange and sub-
stitution and included biologicals 
and biosimilars.7 Guidance on nano-
medicines and nanosimilars was not 
included. Given the growing avail-
ability and use of nanomedicines, 
there is a clear need to revise and up-
date this document to reflect the chal-
lenges in their evaluation.
Implications of nanosimilars 
for pharmaceutical 
practice: the cases of 
liposomal doxorubicin, 
paclitaxel, glatiramoids, and 
iron sucrose
As discussed, the therapeutic 
equivalence of nanomedicines and 
their nanosimilars cannot be as-
sured by pharmaceutical equiva-
lence and bioequivalence due to the 
difficulties associated with their full 
characterization.55 The uncertain re-
lationship between liposomal com-
position and clinical effect has been 
noted for liposomal doxorubicin for-
mulations, raising questions as to the 
feasibility of introducing follow-on 
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products.57 However, in 2012, due to a 
shortage of doxorubicin hydrochloride 
liposome injection (Doxil, Janssen 
Biotech, Inc., Horsham, PA), FDA au-
thorized the temporary importation of a 
“generic” nanosimilar liposomal formu-
lation (Lipodox, Sun Pharmaceutical 
Industries Ltd, Mumbai, India).58 Per the 
product labels, both the reference doxo-
rubicin liposomal injection product 
(Doxil) and its nanosimilar contain 
the same doxorubicin active ingre-
dient and composition of liposomes.59,60 
Currently, 2 different nanosimilar for-
mulations of doxorubicin hydrochloride 
liposome injection are approved in 
the United States (one manufactured 
by Sun Pharmaceutical Industries 
and one by Dr Reddy’s Laboratories 
Inc.).61 The FDA review letters for the 
2 nanosimilar doxorubicin liposome 
products cite approval based on the 
demonstration of bioequivalence to 
the reference product.62,63 In contrast, 
in 2011 Sun Pharmaceutical Industries 
Europe B.V. withdrew its application for 
marketing authorization in Europe for 
the same product after EMA deemed 
the submitted bioequivalence and in 
vivo distribution studies to have pro-
vided insufficient evidence showing 
similarity to the reference doxo-
rubicin hydrochloride liposome in-
jection (Caelyx, Janssen-Cilag, Beerse, 
Belgium).64 Further data have since be-
come available to support the similar 
physicochemical properties, in vivo 
toxicity, pharmacokinetics, and efficacy 
of nanosimilar doxorubicin liposomes 
(Sun Pharmaceutical) and the refer-
ence product, but clinical equivalence 
studies are ongoing,65,66 and as yet, no 
nanosimilar liposomal doxorubicin 
products have been registered by EMA.
In addition, differences in physi-
cochemical characteristics between 
reference products and nanosimilars 
for paclitaxel protein-bound particles 
(Abraxane) and glatiramer acetate 
(Copaxone, Teva) have given rise to po-
tential safety concerns surrounding their 
clinical use.1
IV iron-carbohydrate complexes 
are mainly used for the treatment of 
iron deficiency and iron deficiency an-
emia. These nanomedicines comprise 
a polynuclear iron(III)-oxyhydroxide 
core stabilized by a carbohydrate 
shell.1 Designed to overcome limita-
tions of orally administered iron(II) 
salts,67,68 several products are avail-
able in different markets (eg, iron su-
crose, sodium ferric gluconate, ferric 
carboxymaltose, low-molecular-
weight dextran, iron isomaltoside, 
ferumoxytol), and some follow-on 
versions are authorized in select 
countries. The in vivo drug profile of 
these products is influenced by the 
nanoparticle’s core size and the su-
crose chemistry of the shell, as well 
as the manufacturing process and 
filling procedure.1,68 Stability affects 
nanoparticle distribution, bioavail-
ability, clearance, and iron dissoci-
ation and release, influencing the 
safety of these products and, as a 
consequence, the maximum toler-
ated dose.68 The clinical performance 
of the different IV iron-carbohydrate 
complexes upon administration may 
vary, as reported in the literature and 
summarized in Figure 3. For example, 
IV iron sucrose has been used world-
wide since the first agent in this class 
of drugs (Venofer, Vifor Pharma Ltd, 
Glattbrugg, Switzerland) was intro-
duced in the 1950s.1 Evidence sug-
gests that iron sucrose similars (ISSs), 
which gained access to the market as 
generics, differ from the reference 
product, resulting in varied clin-
ical safety and efficacy and, subse-
quently, pharmacoeco nomics.52,53,69-71 
Physicochemical and preclinical 
studies show differences between the 
reference products and several ISSs in 
terms of oxidative stress and inflamma-
tory responses in the liver, heart, and 
kidneys that may relate to the stability 
of the iron complex.72-74 In particular, 
ISS formulations differ from the refer-
ence product in particle size, size dis-
tribution, and visual appearance when 
diluted for therapeutic use.74 There is 
now considerable evidence that ISS 
products from different manufacturers 
also differ in their clinical safety and 
Figure 2. Formulary selection criteria for nanosimilars. CSTD indicates closed-system transfer device; IT, information 
technology. Reproduced, with permission, from reference 55.
1052  AM J HEALTH-SYST PHARM | VOLUME 78 | NUMBER 12 | JUNE 15, 2021
PRIMERCHALLENGES IN USE OF NANOMEDICINE
efficacy profiles.52,53,69 These findings 
raise questions about the interchange-
ability and therapeutic equivalence of 
ISSs and reference drug products.
The unique and complex physico-
chemical nature of nanomedicines and 
their nanosimilars necessitates strict 
handling, storage, and administration 
protocols to ensure their optimal use. 
Failure to adhere to specific require-
ments for transport and storage (eg, 
temperature, use of an appropriate 
solvent), and handling (eg, restricted 
dilution and speed of administration) 
has the potential to have negative con-
sequences for patients.68,69 Notably, 
during the retrospective study of iron-
deficient women who were postpartum 
or undergoing gynecologic surgeries, 
further dilution of ISS in an effort to re-
duce the frequency of adverse events in 
fact increased their occurrence,69 which 
may reflect the reduced stability of re-
active nanoparticles.
Health-system pharmacists, in -
cluding pharmacists working in acute 
and ambulant care as well as hospital 
pharmacists, are uniquely positioned 
to be responsible for providing insight 
and expertise on nanomedicine char-
acteristics and regulatory challenges 
to ensure best practices in use of these 
innovative pharmaceuticals. To facili-
tate this role, pharmacists need a clear 
understanding of the scientific and clin-
ical evidence underpinning decisions 
around substitution and/or interchange 
of nanomedicine reference products 
and their follow-on products; this high-
lights the important role of pharmacists 
in providing an in-depth scientific view 
on both a nanomedicine’s CQAs and 
their translation into patient-oriented 
best practice medication policies.
Outlook for nanosimilars
The equivalence evaluation of 
nanomedicines is a complex and 
evolving, but not harmonized, area of 
science. Interchangeability and substi-
tutability of nanosimilars are not clearly 
defined, since nanomedicine com-
plexity leads to unknown differences 
in physicochemical characteristics that 
can translate into differences in efficacy 
and safety profiles between reference 
and follow-on products. Through use of 
state-of-the-art analytical techniques, 
two nanomedicines deemed to be of 
comparable physicochemical compos-
ition might be found to have differing 
clinical safety and efficacy profiles. 
This scenario illustrates shortcomings 
in current physicochemical character-
ization techniques and underscores 
the need for additional testing of 
nanosimilars to ensure that both the 
Figure 3. Published studies comparing efficacy and safety of parenteral iron-carbohydrate complexes: (A) head-to-head 
studies using the same total iron dose, (B) head-to-head studies using different total iron doses and/or regimens, and 
(C) retrospective studies, pharmacovigilance database studies, and meta-analyses of real-world evidence. Laboratory 
parameters evaluated included the following: serum ferritin, serum iron, hemoglobin, transferrin saturation, C-reactive 
protein, serum phosphate, mean corpuscular volume, total iron binding capacity, and the heart failure marker N-terminal 
prohormone of brain natriuretic peptide; these were categorized as laboratory parameters when not prespecified in a 
study as a primary efficacy or safety endpoint. The eAppendix provides the literature search strategy and supplemental 
reference list for this figure as well as detailed information on individual studies.
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pharmaceutical equivalence and the 
safety and efficacy profiles match 
those of the reference product. While 
there is growing awareness among the 
scientific community, pharmaceut-
ical industry, and both national and 
international regulatory bodies of the 
challenges presented by nanosimilar 
interchange, regulatory approval pol-
icies for nanomedicines still require 
definition, harmonization, and greater 
clarity to facilitate streamlined ap-
proval processes. Further requirements 
need to be established for the evalu-
ation of therapeutic equivalence of 
nanosimilars and their reference drugs.
Health-system pharmacists are 
uniquely positioned as institutional 
experts on nanomedicine selection, 
handling, and substitution. Specific 
formulary inclusion criteria for the 
evaluation of nanosimilars have 
been published to help guide for-
mulary decision-making.55 However, 
nanomedicines were not included in 
the 2018 FIP policy document outlining 
pharmacists’ authority in product se-
lection on therapeutic interchange 
and substitution.7 Further supportive 
guidance for pharmacists focusing 
on the challenges of substitutability 
and interchangeability of reference 
and follow-on products is needed. We 
propose that the current guidance for 
pharmacists regarding the substitu-
tion of biologics and biosimilars should 
be reviewed and extended to cover 
the selection of nanomedicines and 
nanosimilars.7 The aim is to raise this 
as a topic of discussion during a com-
bined session on nanopharmaceuticals 
at a forthcoming FIP World Congress 
of Pharmacy and Pharmaceutical 
Sciences.
Conclusion
Supportive guidance for phar-
macists focusing on the substitut-
ability and/or interchangeability of 
nanomedicines and their nanosimilars 
is needed. Current FIP guidance for 
pharmacists on therapeutic inter-
change and substitution should be ex-
tended to include nanomedicines and 
nanosimilars.
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